IntriCon Appoints New Independent Director
April 06 2016 - 4:05PM
Business Wire
Experienced M&A Executive Philip Smith
Joined April 5th
IntriCon Corporation (NASDAQ:IIN), a designer,
developer, manufacturer and distributor of miniature and
micro-miniature body-worn devices, today announced that it has
appointed a new independent director, Philip (Phil) Smith, 48, to
its board of directors, effective April 5th. The board now has six
members, five of whom are independent under applicable SEC and
Nasdaq guidelines. Smith will be a member of the audit,
compensation, and nominating and corporate governance committees of
IntriCon’s board.
Smith currently serves as a managing director at the investment
banking firm, Greene Holcomb Fisher, where he focuses on the
healthcare industry. During his prior investment banking experience
at Piper Jaffray, he was heavily involved in M&A and public
equity transactions with industry-leading medical technology and
health services organizations. He brings more than 20 years of
experience in healthcare, including roles in finance and executive
management.
“Phil’s years of diverse experience in the medical device and
healthcare industries —particularly his involvement in cultivating
disruptive channels—will be extremely valuable to IntriCon as we
advance our value hearing health focus, and we’re pleased to
welcome him to the board,” said Mark S. Gorder, president and chief
executive officer of IntriCon. “Coming from the investment banking
world as well as the leadership side of healthcare, Phil has a
unique and valuable perspective on our company, and both the board
and management team look forward to working with him.”
Prior to joining Greene Holcomb Fisher in 2011, Smith was
President and Chief Executive Officer of Angeion Corporation, now
MGC Diagnostics, a global medical technology company. Earlier
experience includes being CEO of DGIMED Ortho, Executive Vice
President of Business Development at Vital Images, and a healthcare
investment banker at Piper Jaffray. He currently serves on the
board of VIDA Diagnostics, a precision pulmonary imaging company,
and has previously held board positions with Delta Dental of
Minnesota and Angeion Corporation.
Smith received his master’s in business administration from the
Wharton School of the University of Pennsylvania and his
undergraduate degree in electrical engineering from the University
of Florida. He is a current member of the board of trustees of The
Minneapolis Foundation.
About IntriCon CorporationHeadquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops and manufactures
miniature and micro-miniature body-worn devices. These advanced
products help medical, healthcare and professional communications
companies meet the rising demand for smaller, more intelligent and
better connected devices. IntriCon has facilities in the United
States, Asia, United Kingdom and Europe. The company’s common stock
trades under the symbol “IIN” on the NASDAQ Global Market. For more
information about IntriCon, visit www.intricon.com.
Forward-Looking StatementsStatements made in this release
and in IntriCon's other public filings and releases that are not
historical facts or that include forward-looking terminology are
"forward-looking statements" within the meaning of the Securities
Exchange Act of 1934, as amended. These forward-looking statements
may be affected by known and unknown risks, uncertainties and other
factors that are beyond IntriCon's control, and may cause
IntriCon's actual results, performance or achievements to differ
materially from the results, performance and achievements expressed
or implied in the forward-looking statements. These risks,
uncertainties and other factors are detailed from time to time in
the company's filings with the Securities and Exchange Commission,
including the Annual Report on Form 10-K for the year ended
December 31, 2015. The company disclaims any intent or obligation
to publicly update or revise any forward-looking statements,
regardless of whether new information becomes available, future
developments occur or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160406006397/en/
At IntriCon:Scott Longval, CFO,
651-604-9526slongval@intricon.comorAt PadillaCRT:Matt Sullivan,
612-455-1709matt.sullivan@padillacrt.com
Intricon (NASDAQ:IIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intricon (NASDAQ:IIN)
Historical Stock Chart
From Apr 2023 to Apr 2024